ClinicalTrials.gg
CompletedNCT02491268Updated Dec 4, 2020

A Trial of Cilostazol in Patients With Mild Cognitive Impairment (COMCID)

A Phase 2 interventional study of Cilostazol and Placebo in Mild Cognitive Impairment, sponsored by National Cerebral and Cardiovascular Center, Japan. Completed at 1 site in Japan. Open to participants aged 55 Years to 84 Years. Per ClinicalTrials.gov, last updated 2020-12-04.

Sponsored by National Cerebral and Cardiovascular Center, Japan · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
166
Allocation
Randomized
Ages
55 Years to 84 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Cognitive Dysfunction with a site in Japan — 4 open to participants now, 9 under way, 6 of them phase 3. Cognitive Dysfunction · Japan.

Enrollment
19th of 26
166 · median 378
Started
2015
with 1 other
Phase 2
9 of 28
1 open now
Registered
9th of 28
by date

Among the 28 studies in Cognitive Dysfunction with a site in Japan, this one is the 19th largest by enrollment of the 26 interventional ones that give a count, is one of 2 that started in 2015, is one of 9 in phase 2, and was the 9th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

4 of the 28 studies in Cognitive Dysfunction with a site in Japan are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 55 Years to 84 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Cognitive Dysfunction with a site in Japan, or all of them as a file.
02

Study summary

Epidemiological, clinicopathological and animal studies show that vascular disease in various forms contributes to cognitive decline. Increasing age is the strongest risk for dementia irrespective of whether it results from a vascular etiology or neurodegenerative disease processes such as in Alzheimer's disease (AD). AD and vascular cognitive impairment, the two most common causes of dementia, represent two extremes of a spectrum of disorders; however, a number of entities, which possess varying degrees of neurodegenerative and vascular pathologies, occur in between. The pure forms of the disorders are preferred for convenience to label, treat or manage but conditions within the spectrum are the norm rather than the exception as dementia advances. Therefore, combinatorial therapy directed at both vascular and neurodegenerative aspects of dementia is a promising approach for the treatment of dementia in the elderly.

Cilostazol acts as an antiplatelet agent and has other pleiotropic effects based on phosphodiesterase-3-dependent mechanisms. Increasing evidence suggests that cilostazol offers endothelial protection, via pleiotropic effects. Intriguingly, cilostazol has been shown to decrease amyloid beta (Abeta) accumulation and protect Abeta-induced cognitive deficits in an experimental model. In a pilot study of 10 patients with moderate AD (mean MMSE score, 11.9 points) who received donepezil, cilostazol add-on treatment for 5-6 months demonstrated significantly increased MMSE score in comparison to baseline. Moreover, cilostazol was shown to be effective in preventing cognitive decline in patients with AD with cerebrovascular diseases, mild cognitive impairment (MCI), and mild dementia who received donepezil.

These results highlight the need for a comprehensive prospective cohort study to analyze the effect of cilostazol on the preservation of cognitive function in patients with early-stage cognitive impairment, namely MCI.

03

Conditions studied

  • Mild Cognitive Impairment
04

Who can participate

Ages eligible
55 Years to 84 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between 55-84 (inclusive)
  2. Study partner who sufficiently knows the daily life of the patient
  3. Patients with MCI who satisfy the core clinical criteria of National Institute for Aging-Alzheimer Association for MCI (nearly equivalent to mild neurocognitive disorder in , Fifth Edition) and who also satisfy the following three criteria:

    i) Memory complaint by subject or study partner Type I: Memory complaint by subject that is verified by a study partner Type II: Otherwise, memory complaint by study partner with the evidence of memory impairment Note) Memory complaint by subject that is not verified by study partner will be excluded.

    ii) (MMSE) scores between 22 and 28 (inclusive) iii) Clinical Dementia Rating (CDR) = 0.5

  4. Written provided for study participation

Exclusion criteria

Exclusion Criteria:

  1. Parkinson's disease, Huntington's disease, normal pressure hydrocephalus, progressive supranuclear palsy, epilepsy, multiple sclerosis, cerebral infection, or subsequent complication caused by head trauma.
  2. Findings of multiple infarction, brain tumor, or subdural hematoma on MRI performed within 48 weeks before provisional registration.
  3. for MRI such as magnetic body or metal.
  4. History of major depression or bipolar disorder within 48 weeks before provisional registration, alcohol or other substance abuse within 96 weeks before provisional registration, other diseases or unstable conditions.
  5. Poorly controlled diabetes mellitus (>9.0%).
  6. Cognitive impairment due to deficiency of vitamin B12 or folate.
  7. Neurosyphilis.
  8. Cognitive impairment due to thyroid function abnormality.
  9. Psychoactive drugs within 4 weeks before provisional registration.
  10. Oral anticoagulants within 4 weeks before provisional registration.
  11. Double antiplatelet therapy (cf. Aspirin, Clopidogrel but not Cilostazol) within 4 weeks before provisional registration.
  12. Poorly controlled diabetes mellitus treated with insulin within 4 weeks before provisional registration.
  13. Episode of hypoglycemic attack with loss of consciousness within 4 weeks before provisional registration.
  14. Anti-dementia drugs within 4 weeks before provisional registration.
  15. Participation in any other new drug study for Alzheimer's disease.
  16. Current bleeding or bleeding disorders.
  17. Congestive heart failure.
  18. Coronary artery stenosis.
  19. Sustained high blood pressure within 2 weeks before provisional registration.
  20. History of drug to Cilostazol.
  21. The subject or the subject's spouse pregnant or breast-feeding at the time of provisional registration.
  22. Difficulty in neuropsychological tests due to hearing or visual impairment.
  23. Considered by the principal investigator to be ineligible.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
166 participants (actual)

Study arms

  • Experimental
    Cilostazol 50mg B.I.D.

    After the registration, the Site Investigators should start protocol treatment within 28 days including the day of registration. Protocol treatment defines as follows; Investigational Treatment: Cilostazol 50mg B.I.D. p.o. 96 Weeks

    Drug: Cilostazol

  • Placebo comparator
    Placebo B.I.D.

    After the registration, the Site Investigators should start protocol treatment within 28 days including the day of registration. Protocol treatment defines as follows; Comparative Treatment: Placebo B.I.D. p.o. 96 Weeks

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in Mini Mental State Examination (MMSE)

    Time frame: 96 weeks

Secondary outcomes

  1. Conversion from MCI to All-cause Dementia

    Dementia is diagnosed clinically when the patient meets core clinical criteria for dementia with reference to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition.

    Time frame: up to 96 weeks

  2. Cognitive Decline on Clinical dementia rating-sum of boxes (CDR-SB)

    Time frame: baseline, 48 weeks, and 96 weeks

  3. Cognitive Decline on Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) 14

    Time frame: baseline, 48 weeks, and 96 weeks

  4. Cognitive Decline on Logical Memory subtest of the Wechsler Memory Scale-Revised (WMS-R)

    Time frame: baseline, 48 weeks, and 96 weeks

  5. Functional Decline on Alzheimer's disease Cooperative Study scale for activities of daily living in MCI (ADCS-MCI-ADL)

    Time frame: baseline, 48 weeks, and 96 weeks

  6. Hippocampal volume

    Magnetization prepared rapid acquisition with gradient echo is used to assess hippocampal volume.

    Time frame: baseline and 96 weeks

Other outcomes

  1. Cognitive Decline on Free and Cued Selective Reminding Test (FCSRT)

    Time frame: baseline, 48 weeks, and 96 weeks

  2. Cognitive Decline on Trail making test (TMT)

    Time frame: baseline, 48 weeks, and 96 weeks

07

Study locations

1 site
  • National Cerebral and Cardiovascular Center
    Suita, Osaka 564-8565, Japan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2015 to primary completion in Aug 2020, 63 months.

Of 145 non-industry phase 2 interventional studies under Cognitive Dysfunction, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 64. This study's 63 months is above that.

Counting every sponsor, half of 187 studies reached it within 42 months; a quarter within 22 and three quarters within 62.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2015
First posted
Jul 8, 2015
StartActual
May 1, 2015
Primary completionActual
Aug 14, 2020
CompletionActual
Dec 1, 2020
Last update
Dec 4, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02491268
Lead sponsor
National Cerebral and Cardiovascular Center, Japan
Responsible party
Masafumi Ihara (Chief Physician (Head of Neurology), National Cerebral and Cardiovascular Center, Japan) — Principal investigator
First posted
Jul 8, 2015
Start date
May 1, 2015
Primary completion
Aug 14, 2020
Completion
Dec 1, 2020
Last update
Dec 4, 2020

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cilostazol

Start the discussion